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OPEN
ORIGINAL ARTICLE
Stem cell-derived neurons from autistic individuals with
SHANK3 mutation show morphogenetic abnormalities during
early development
A Kathuria1, P Nowosiad1, R Jagasia2, S Aigner3, RD Taylor4,5, LC Andreae4,5, NJF Gatford1, W Lucchesi6, DP Srivastava1,5 and J Price1,5,7
Shank3 is a structural protein found predominantly at the postsynaptic density. Mutations in the SHANK3 gene have been
associated with risk for autism spectrum disorder (ASD). We generated induced pluripotent stem cells (iPSCs) from control
individuals and from human donors with ASD carrying microdeletions of SHANK3. In addition, we used Zinc ﬁnger nucleases to
generate isogenic SHANK3 knockout human embryonic stem (ES) cell lines. We differentiated pluripotent cells into either cortical or
olfactory placodal neurons. We show that patient-derived placodal neurons make fewer synapses than control cells. Moreover,
patient-derived cells display a developmental phenotype: young postmitotic neurons have smaller cell bodies, more extensively
branched neurites, and reduced motility compared with controls. These phenotypes were mimicked by SHANK3-edited ES cells and
rescued by transduction with a Shank3 expression construct. This developmental phenotype is not observed in the same iPSC lines
differentiated into cortical neurons. Therefore, we suggest that SHANK3 has a critical role in neuronal morphogenesis in placodal
neurons and that early defects are associated with ASD-associated mutations.
Molecular Psychiatry (2018) 23, 735–746; doi:10.1038/mp.2017.185; published online 26 September 2017
INTRODUCTION
Autism spectrum disorder (ASD) is a group of neurodevelop-
mental disorders deﬁned by restrictive repetitive behavior, deﬁcits
in social interaction and impaired communication. The etiology of
ASD is not well understood. There is, however, a strong genetic
basis to ASDs, as indicated by the high concordance rate between
twins (up to 90% between monozygotic and 20% between
dizygotic twins).1 Between 10% and 20% of ASD patients carry
pathogenic copy number variant,2,3 and a high proportion of
these involve genes encoding synaptic proteins. This has led to
the suggestion that ASD is a disorder of synaptogenesis.4
One such gene is SHANK3, which encodes a scaffolding protein
of the postsynaptic density (PSD). It comprises ﬁve main domains:
N terminal ankyrin repeats (ANK), PDZ domain, sterile alpha motif
(SAM) domain, SRC Homology (SH3) domain, and proline-rich
domain (pro).5,6 At the PSD, it interacts with NMDAR via the
PSD95/GKAP (guanylate kinase-associated protein) complex that
binds to its PDZ domain. This complex also binds the GluR1
subunit of the AMPAR (α-amino-3-hydroxy-5-methyl-4-isoxazole-
propionic acid receptor). In addition, the proline-rich domain of
SHANK3 binds to the mGluR5 (metabotropic glutamate receptor)
via Homer1 (Homer Scaffolding Protein 1).6–9 This evidence
suggests that SHANK3 recruits various synaptic receptors to the
PSD and is thus a pivotal player in building the glutamatergic
synapse.
The SHANK3 gene is found at the 22q13 locus in humans, and
41000 cases of 22q.13 deletion have been reported. In all, 75% of
these have ASD and 95% display severe developmental delay.10
Conversely, 2% of autistic individuals carry a harmful deletion in
the SHANK3 gene.11–13 In another cohort study carried out on 133
patients from USA and 83 patients from Italy, 5 detrimental
mutations were discovered in the SHANK3 gene with an
occurrence rate of 2.3%.14 Additionally, two recent studies have
shown that SHANK3 is the most underdiagnosed, highly penetrant,
monogenic cause of ASD. The ﬁrst study used whole-genome
sequencing to reveal a de novo SHANK3 mutation in familial ASD.15
The second evaluated 32 patients and revealed SHANK3
haploinsufﬁcency as the monogenic cause of ASD in 0.5% of these
cases.16 Deletion in the SHANK3 gene has been shown to cause
Phelan McDermid Syndrome (PMDS), a neurodevelopmental
disorder characterized by global developmental delay, speech
delay, intellectual disability, poor motor coordination and ASD.17
Induced pluripotent stem cells (iPSCs) permit the study of the
etiology of neurodevelopmental disorders using cells in culture to
reproduce phenotypes associated with speciﬁc disease risk
alleles.18 Phenotypes associated with PMDS have been studied
in iPSC lines generated from two patients. This study found that
iPSC-derived PMDS neurons had a reduced expression of SHANK3
and impaired excitatory synaptic transmission.19 Both amplitude
and frequency of miniature excitatory postsynaptic currents were
signiﬁcantly reduced, and histochemical staining revealed a
decrease in both presynaptic and postsynaptic puncta, suggesting
that these neurons made fewer synapses. Analysis of genetically
engineered heterozygous and homozygous SHANK3 mutations in
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human neurons has revealed alterations in neuronal morphology
and synaptic connectivity. Speciﬁcally, the Ih channel is severely
impaired.20 Both these studies examined cortical neurons and
focused on the later stages of neuronal development, as the
neurons become synaptically active.
Shank3 knockout mice have also demonstrated utility in
elucidating elements of ASD.21–25 These mice exhibit abnormal
behavior, synaptic dysfunction, abnormal spine morphology,
synapse formation and deﬁcits in learning. Both the animal and
iPSC studies of SHANK3 indicate that ASD risk alleles are associated
with synaptic deﬁcits. This tends to conﬁrm the synaptogenic
deﬁcit hypothesis for autism. No studies, however, have examined
neural development at stages before the onset of synaptogenesis,
even though we know that SHANK3 is expressed from neural
tube stages in vivo.26 The question remains, therefore, of when
SHANK3 deletions ﬁrst impact neural development and what
role any putative early phenotypes might have on later
synaptogenesis?
Most autism studies focus on neuronal defects within cortex,
hippocampus and striatum. Nevertheless, there is evidence that
the hypothalamus may be important in ASD. An MRI study where
52 autistic children were compared with 52 matched controls
found diminished gray matter in the hypothalamus.27 Another
study reported that gestational hypothyroxinemia in rodents
induced impaired cortical neuronal migration. Neuronal migration
deﬁcits have been reported in autistic children.28 Thyroid-
stimulating hormone is produced by the hypothalamus and
regulates thyroid hormone production.29 Moreover, low levels of
thyroid-stimulating hormone during mid-pregnancy have been
shown to increase signiﬁcantly the odds of a child being
diagnosed with autism.30 Using mass spectrometry and liquid
chromatography, the concentrations of three sex steroid hor-
mones, progesterone, testosterone and 17α-hydroxy-progester-
one, have been studied in autistic children. All of these were found
elevated.31 gonadotropin-releasing hormone (GnRH) produced by
the hypothalamus is a precursor to these hormones. All the above
studies have clearly established a link between hypothalamus and
autism that has not yet been investigated in human cells.
To address these issues, we track the development trajectory of
GnRH+ neurons (as derived from the olfactory placode) generated
from human iPSCs lines. These lines were produced from hair root
biopsies from two categories of individuals: three healthy control
individuals and two autistic patients with heterozygous deletions
in the SHANK3 gene.32 iPSCs were differentiated into neurons and
their structural and functional development was tracked during
the various stages of neuralization. The study reveals that, during
early neuronal development, SHANK3 iPSC-derived neurons have a
smaller cell soma but more and longer primary neurites than
control cells. Further, embryonic stem (ES) cell lines engineered to
carry homozygous or heterozygous deletions of the SHANK3 gene
give rise to neurons with similar morphogenetic deﬁcits to those
seen in the SHANK3 patient neurons. Not only were the
morphogenetic deﬁcits in iPSCs rescued by overexpressing
SHANK3, but later synaptic deﬁcits were similarly rescued by this
overexpression. Thus this study presents the novel idea that
haploinsufﬁency of SHANK3 during early neuronal development
compromises the structural integrity of neurons and leads to later
synaptic deﬁcits in mature neurons.
MATERIALS AND METHODS
iPSC generation and olfactory placodal neuronal differentiation
The iPSC clones were generated using a lentiviral construct from
keratinocytes from two individuals with ASD and three healthy individuals,
as previously reported32 (Supplementary Table 1 and 2). Neural
differentiation of iPSCs was performed using the modiﬁed version dual
SMAD inhibition protocol.33 Brieﬂy, with cells at 100% conﬂuency, the
medium was changed to N2/B27, and SMAD and Wnt agonist were added
(SB431542-10 μM, XAV939-2 μM and Dorsomorphin 1 μM). Thereafter, the
medium was supplemented with SMAD inhibitors and changed every day
for 7 days. On day 8, the cells were split 1:1 onto geltrex substrate, giving
rise to a sheet of neural progenitor cells. The cells were then fed alternate
days with N2/B27 and once conﬂuent they were split. On day 20, the cells
were transferred to polyD-lysine and laminin (10 μg ml− 1), DAPT 10 μM and
B27 media to differentiate into neurons. Immature neurons emerged
around day 26. Control neurons generated from this protocol show normal
neuronal electrical activity as shown in Supplementary Figure 1.
High-content image screening
Dissociated neurons were plated at 1–1.5 × 103 neurons per well on polyD-
lysine and laminin-coated 96-well tissue culture plates. The cells were ﬁxed
and stained for neuronal markers Tuj1 (Biolegend, Berkshire, UK) and DCX
(doublecortin; Abcam, Cambridge, UK). A quantitative imaging analysis of
the young neurons was conducted through the Cell Insight machine at
× 10 magniﬁcation using the Cell Scan software (Cellomics NX11110,
Pittsburgh, PA, USA). The following morphological features were assessed
for both the patient and control: cell soma area and the number of primary
neurites per neuron. At least 10 ﬁelds were randomly selected and scanned
per well of a 96-well dish. To identify and remove any false readings
generated by the Cell Insight, three random SHANK3 and control wells
were selected and counted manually (blind to genotype). A histogram was
generated from the manual count depicting the distribution of the cell
soma area for both control and SHANK3 at day 30 of neuralization. The
average error rate percentage is shown in Supplementary Figure 8.
Neurite outgrowth assay via time-lapse imaging
Neurons were grown on 15 mm glass bottom dish (Ibidi, Planegg,
Germany) and placed in an environmentally controlled stage. Time-lapse
images of cells were taken over a period of 48 h at × 20 magniﬁcation
using Nikon Biostation IM-Q (London, UK). Phase-contrast images were
taken every hour for 48 h. Each neuron was then traced and measured for
12 h using the neurite outgrowth software (Metamorph, Molecular
Devices, Sunnyvale, CA, USA). The following parameters were measured:
primary neurite formation and elimination, primary neurite extension and
retraction (μm h− 1), and cell soma speed (μm h− 1).
Immunocytochemistry
Cells were ﬁxed with 4% paraformaldehyde, washed (3 × ) with phosphate-
buffered saline, permeabilized with 0.1% triton-X (15 min room tempera-
ture) and blocked using 5% donkey serum (1 h room temperature). Primary
antibodies were diluted in 1% donkey serum and applied (overnight at
Figure 1. Neuralization (a). The chart depicts the neuralization protocol used and indicates the ﬁve stages of neuralization. These are the
induced pluripotent stem (iPS) cell (day 0), the neural progenitors (day 12), the rosette structure (day 18/19), the doublecortin positive neurons
(day 26) and the synaptically active neuronal stage (day 70). (b) Day 30 placodal control neurons positive for Lhx6, GnRH1, MAP2, DAPI (4,6-
diamidino-2-phenylindole) and negative for CTIP2 (scale= 25 μm). (c) Number of GnRH1-positive cells/total no. of nuclei. (d) Number of Lhx6-
positive cells/total no.of nuclei. (e) Number of both Lhx6- and GnRH1-positive cells/total no. of nuclei. (f) Cortical gene expression for control
cortical neurons at day 30 of neuralization. (g) Olfactory placodal gene expression for control placodal neurons at day 28 of neuralization. Both
graphs show fold change relative to day 0 control P1 C2, assessed via quantitative PCR (qPCR). (h) SHANK3 fold change for control and SHANK3
neurons at days 15, 25 and 40 of neuralization, relative to Control P2 C3 at day 15, assessed via qPCR. Data are expressed as mean± s.e.m. (i)
Western blotting of SHANK3 at day 30, normalized to glyceraldehyde 3-phosphate dehydrogenase (GAPDH). Three control lines were compared
with 2 SHANK3 lines with two biological replicates, Control P1 C2 stands for Control patient 1 clone, Control P2 C2 stands for Control patient 2
clone 2, Control P5 is control patient 5 and SHANK3 P1 C1 is SHANK3 patient 1 clone1 and SHANK3 P2 C1 is SHANK3 patient 2 clone 1.
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4 °C). The primary antibodies used are described in Supplementary Table 3.
Secondary antibodies were diluted (1:500) in 1% donkey serum and
applied for 1 h at room temperature. The following secondary antibodies
were used: Alexa 488, 594, and 647 (Invitrogen, Carlsbad, CA, USA).
Neurons were visualized using either Olympus ﬂuorescence microscope
(Southampton, UK) or a laser scanning confocal microscope equipped with
405/488/594/633 nm lasers (Leica System, Wetzlar, Germany). Images
within an experiment were acquired with identical acquisition setting at
× 40, × 63 and ×100.
Synaptic puncta measurement
Images were taken from the 63 × objective on a Leica TCS SP5 Confocal
Laser Scanning Microscope coupled with the LAS AF lite software (Wetzlar,
Germany). We used 386, 488 and 594 nm lasers, along with the appropriate
excitation and emission ﬁlters. These settings were kept consistent while
taking images from all cultures. Acquired images were converted into
eight-bit tiff ﬁles and analyzed with the Image J software version 7.3
(Rockville, MD, USA). At least two portions of neurites, length not
exceeding 50 μm were selected. This region was added to region of
interest manager. Following this, the images were thresholded such that
the synaptic puncta would turn black and the background would turn
white. The thresholded images were then analyzed through ‘Analyze
Particles’. The size limit at this point was set up to 0.03–3 μm2. This meant
that only punctas with a size of 0.03–3 μm2 would be measured. The
summary from ‘Analyze particles’ gave the total number of punctas
observed in the region of interest. These steps were repeated until the
whole neuron was captured. The data obtained were analyzed as the
number of punctas/50 μm.
Construction of SHANK3 lentiviral vector, production and infection
The full-length SHANK3 human cDNA was synthesized by GENEWIZ
(Plainﬁeld, NJ, USA) with Myc fused to the N terminal and then cloned into
pCDH-EF1-MCS (CD502-1A System Biosciences, Palo Alto, CA, USA). The
vector map and SHANK3 sequence has been provided in supplementary
Figure 6. Lentiviruses were generated with a three-plasmid transfection
system using Lipofectamine LTX (Life Technologies, Camarillo, CA, USA) in
HEK293FT cells. Twelve hours after transfection, supernatants were
collected. Viral particles were concentrated using Lenti-X concentrator
(Clontech, Mountain View, CA, USA), aliquoted (100 μl) and stored at − 80 °
C. Different amounts of virus (5–50 μl) were placed on ~70% conﬂuent
neurons for 2 days. Approximately 80% of the cells in one well of a 96-well
dish stained positive for Myc on addition of 5 μl of virus. We used 5 μl
of SHANK3-myc virus to transduce at day 20. The medium was replaced
24 h later. Neurons were analyzed after 10 days. Veriﬁcation of SHANK3
overexpression virus was performed via immunocytochemistry
(Supplementary Figure 7).
Genetic engineering of ES cell lines and validation (es shank3 − /−
and es shank3+/− )
Constructs. Plasmids encoding a pair of zinc ﬁnger nucleases (ZFNs)
targeting the 5′ end of exon 21 of SHANK3 (CompoZr Custom ZFN) were
from Sigma. The ZFN recognition site is GGCCCTTCCGTCCGCaggggaGGA
CGAGAAGCTGGCG, where upper and lower case letters denote the ZFN
binding and cut sites, respectively. mRNA encoding ZFNs targeting exon 1
of the PPP1R12C (also known as AAVS1) locus was from Sigma (St Louis,
MO, USA; CompoZr Targeted Integration Kit). Targeting constructs
harboring a loxP-ﬂanked phosphoglycerate kinase promoter (PGK)-driven
neomycin phosphotransferase cassette (loxP-PGK-neo-loxP, surrounded on
either side by 400 bp of sequence homologous to the genomic locus
immediately adjacent to the ZFN cut sites, were synthesized de novo,
subcloned into the EcoRV site of pUC57 and sequence-veriﬁed (GenScript,
Piscataway, NJ, USA).
Genome targeting. One microgram each of the ZFN plasmids (for SHANK3
targeting) or one vial of ZFN mRNA (for AAVS1 targeting) and 1 μg of
targeting vector were introduced into 2 × 106 SA001 human ES cells by
electroporation (4D Nucleofector with X Unit, P3 Solution, program
DN-100; all from Lonza, Basel, Switzerland), and cells plated in the
presence of 10 μM Y-27632. Selection with G418 (Life Technologies) was
started 2 days later. After 10 days of selection, resistant colonies were
manually isolated, transferred to multiwell plates and separately cultured
without selection. Clones with site-speciﬁc cassette insertions were
identiﬁed by PCRs from genomic DNA with the following oligonucleotide
primer pairs: SHANK3 locus, SHANK3 _F1+Neo_R and Neo_F+SHANK3 _R1;
AAVS1 locus, AAVS1_F+Neo_R and Neo_F+AAVS1_R. Correctly targeted
clones were further subcloned by limited dilution, expanded and
re-analyzed by genomic PCR. Double knockouts were generated by
targeting clonal isolates of single knockouts with the same SHANK3-
targeting ZFNs and targeting constructs harboring a loxP-ﬂanked
PGK-driven puromycin N-acetyl-transferase cassette (loxP-PGK-puro-loxP.
Selection was with puromycin. All lines were conﬁrmed to be karyotypi-
cally normal by G-banding (WiCell, Madison WI, USA). Quantitative PCR
analysis was performed to verify SHANK3 expression in the lines generated
(Supplementary Figure 9).
Data collection and statistics. All experiments were replicated at least
three times, as indicated in the ﬁgure legends. We performed quality
control on each neuronal culture: if the cells were not at least 80% positive
for Tuj1 (neuronal-speciﬁc β-iii tubulin marker), the culture was discarded.
Cultures were randomly selected for assay and were processed blind. The
statistical analysis used is reported in the ﬁgure legends. The normal
distribution was checked using Kolmogorov–Smirnov test. The statistical
analysis was carried out using Prism6 (La Jolla, CA, USA) and SPSS (Coppell,
TX, USA).
RESULTS
SHANK3 is expressed during early neuronal development
Human iPSC lines from hair keratinocytes, from two donors
diagnosed with ASD and carrying microdeletions of the SHANK3
locus, have been previously described.32 Controls came from
neurotypical donors. We used a modiﬁed version of ‘dual SMAD
inhibition’ to direct iPSCs along a neuronal pathway. The
modiﬁcation involved the inclusion of XAV (2 μM) and dorsomor-
phin (1 μM), which we have shown independently to drive
differentiation toward an olfactory placodal fate (Figure 1a). By
day 26, neuronal-speciﬁc β-iii-tubulin positive (Tuj1) neurons could
be identiﬁed, and by day 70, neurons were positive for synaptic
markers. Immunocytochemical analysis of the cells at day 30 of
neuralization revealed markers positive for placodal neurons
(Lhx6, GnRH1 and Map2: Figures 1b–e). The cells did not express
CTIP2, a marker absent from placodal cells but expressed in dorsal
telencephalon. We also performed gene expression analysis for
both cortical and olfactory placodal control neurons (Figures 1f
and g). Placodal neurons expressed GnRH1, Nkx2.1 and TRH but
showed marginal expression of TBR1 expression, a gene involved
in cortical development. The converse expression pattern was
seen in cortical neurons: high expression of TBR1, and minimal
expression of GnRH1, Nkx2.1 and TRH.
A previous study19 reported a decrease in the number of
synaptic puncta in cortical neurons derived from individuals with
PMDS. We asked, therefore, whether our cells, with a smaller
microdeletion, showed a similar phenotype. We compared the
expression of synaptic markers in 70-day-old placodal neurons
derived from both control and SHANK3 iPSCs. There were fewer
puncta labeled with both presynaptic and postsynaptic markers
(Synaptophysin and Homer1) in the SHANK3 patient neurons
compared with control (Synaptophysin/50 μm: 94.7 ± 6.7 per
50 μm of SHANK3 neurite vs 208.4 ± 14.0 control and Homer/
50 μm: 70.6 ± 6.0 SHANK3 vs 180.3 ± 10.9 control) consistent with
published data (Figures 4f–h).
Having conﬁrmed the synaptic deﬁcit, we asked how early
during differentiation a phenotype could be observed. First, we
asked when during development SHANK3 was expressed.
Quantitative PCR of control cells indicated that SHANK3 is
expressed at days 15 and 25 in neural progenitors and early
postmitotic neurons, respectively. In the SHANK3 cells, expression
was lower and delayed. Expression is essentially zero at both day
15 and 25 time points and is still approximately 30-fold lower than
control at day 40 (Figure 1h). The western blotting analysis of day
30 neurons conﬁrmed the expression of SHANK3 in both control
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Figure 2. Morphological deﬁcits found in immature SHANK3 patient neurons. (a) Control neurons cell soma. (b) SHANK3 neurons cell soma
(scale= 10 μm, day 30 neurons stained with DCX (doublecortin; green) and DAPI (4,6-diamidino-2-phenylindole; gray)). (c and d) Bare images
of Control and SHANK3 DCX+ neurons at day 30 taken during high-content screening, scale= 200 μm. (e) High-content screening performed
to ﬁnd changes in cell soma area μm2 from day 22 (late neural progenitors) to day 30 (immature neurons). Data are represented as mean± s.e.
m., Mann–Whitney U-test was performed for each time point; the only difference was seen at day 30. ***Po0.001. (f) High-content screening
performed to ﬁnd out the number of primary neurites per neuron from day 22 (late neural progenitors) to day 30 (immature neurons). Data
are represented as mean± s.e.m. Unpaired Student’s t-test with Welch’s correction was performed for each time point; the only difference was
seen at day 30. ***Po0.001. (g and i) The number of primary neurites per neuron at days 27 and 30. Data are represented as mean± s.d.,
***Po0.001, Student’s t-test was performed, Control neurons n= 26.0 × 103; shank3 neurons n= 30.0 × 103. (h and j) Cumulative frequency
distribution of cell soma area at days 27 and 30. (***Po0.001, Kolmogorov–Smirnov test was performed, Control neurons n= 26.0 × 103;
shank3 neurons n= 30.0 × 103). We performed three biological replicates. We compared ﬁve control lines with four SHANK3 lines, three control
lines with two clonal replicates and two SHANK3 lines with one clonal replicate of each.
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and patient lines (Figure 1i). Notably, at day 30 postmitotic
neurons appear, and the control neurons showed an increased
expression of SHANK3 when compared with SHANK3 patient lines
(Supplementary Figure 3A). These results demonstrate that
SHANK3 is expressed considerably before the onset of synapto-
genesis in these cells and that the shortfall in the expression in the
patient lines at these early stages is considerably greater than the
twofold difference reported at synaptic stages in the PMDS lines.
Morphogenetic deﬁcits during early development of SHANK3
patient
To observe the neuronal development of placodal cultures, we
assessed various morphological aspects of the control and SHANK3
patient neurons. At days 30 and 45 of neuralization, cells were
transfected with green ﬂuorescent protein and visualized with
ﬂuorescence microscopy. The transfection efﬁciency was the same
for both control and SHANK3 at approximately 2%. We counted: the
number of primary neurites per neuron, average neurite length
(μm), and average cell soma diameter (μm). At both stages, the cell
diameter (μm) was smaller in the SHANK3 neurons while the
neurite length (μm) and the mean number of neurites was higher
(Supplementary Figure 2E and F (i–iii)).
In order to automate this assay and to assess the entire
neuronal population rather than the 2% transfected cells, we
conﬁgured a high-content cytometry assay to assess these same
morphogenetic parameters at four stages of neutralization: days
22 (late neural progenitors), 25, 27, and 30 (immature neurons,
Figures 2a–d). No differences were apparent between SHANK3 and
control cells at days 22, 25 or 27 (Figures 2e and f). At day 30,
however, we observed a signiﬁcantly smaller cell soma area
(Figure 2j) and higher number of primary neurites per neuron
(Figure 2i) in the SHANK3 lines compared with control. This
conﬁrmed our pervious observation on day 30 cells and conﬁrmed
this time point as the earliest at which the phenotype could be
observed.
Next, we wanted to know whether the morphogenetic deﬁcits
we observed were speciﬁc to the placodal cells. For this, we
generated cortical neurons and compared the structural devel-
opment in control vs the SHANK3 patient lines. The cortical
neurons were CTIP2 positive (Supplementary Figure 4C). The cell
soma area and number of primary neurites per neuron were
analyzed using high-content imaging at day 30 of neuralization
as the placodal cultures. There were no signiﬁcant differences
between the control and SHANK3 patient cortical neurons
(Supplementary Figures 4D and E). Analysis of neurite length,
however, revealed that the SHANK3 patient cortical neurons had
signiﬁcantly shorter neurites than the controls (Supplementary
Figure 4F). These ﬁndings in cortical cells concur with the recent
study of Yi et al.20
Neurite outgrowth is altered in immature SHANK3 patient placodal
neurons
The increased neurite number in SHANK3 patient cells could result
from increased neurite formation, decreased elimination or both.
We compared the rate of neurite formation and elimination
(neurite h− 1) and extension and retraction (μm h− 1) in control and
SHANK3 patient neurons at day 30 of neuralization over a 12-h
period using time-lapse imaging (Figures 3a and b). The rate of
formation of the primary neurite was signiﬁcantly higher in
SHANK3 patient neurons than in controls, whereas the rate of
primary neurite elimination was signiﬁcantly lower (Figures 3c, g
and h). There was, however, no difference between the patient
and control lines in the rate of secondary branch formation and
elimination (Supplementary Figures 4A and B). Similarly, the rate
of extension of primary neurite length was signiﬁcantly higher in
SHANK3 patient neurons, whereas the rate of primary neurite length
retraction was signiﬁcantly lower (Figures 3d–f). Thus SHANK3
patient neurons show an increased rate of primary neurite formation
and an increase in neurite length extension. This corroborates our
ﬁnding of increased number and length of primary neurites.
During early development, GnRH neurons pass through the
nasal placode to the hypothalamus,34 and this migratory
mechanism has been shown to involve the movement of the cell
soma along the neurite.35,36 Using time lapse, we observed a
similar movement of cell somata along neurites. We calculated the
speed of the cell soma movement in control and SHANK3 neurons
and discovered that the SHANK3 neurons showed a signiﬁcant
reduced soma speed compared with control (Figure 3i).
The time-lapse study also allowed us to analyze in real time the
emergence of the difference in cell soma area in neurons from
SHANK3 patients. We calculated the average rate of change in cell
soma area over the period of 12 h (μm2 h− 1) in control and
SHANK3 patient-derived cells and found the rate to be
signiﬁcantly lower in the SHANK3 patient neurons (Figure 3j).
Thus the SHANK3 cells grew more slowly than controls.
SHANK3 rescue of the morphogenetic phenotype.
To conﬁrm that the morphogenetic phenotype we have observed
was indeed a consequence of SHANK3 haploinsufﬁciency, we
attempted to rescue the phenotype by SHANK3 overexpression.
We infected the SHANK3 patient placodal neurons with a lentivirus
encoding the full-length SHANK3 (ORF) where the N terminal had
been fused to Myc (Supplementary Figure 6). Non-infected
SHANK3 neuronal cultures were included as controls. The neurons
were infected at day 20/21 of neuralization and the virus was
removed after 24 h.
On day 30, neurons were ﬁxed and stained for Myc to identify
transduced cells and with anti-DCX to identify immature neurons
(Figure 4a). Roughly 80% of neurons were Myc+. We programmed
the high-content imaging platform to count cells that were
positive for Myc and DCX+. We measured the cell soma area (um2)
Figure 3. SHANK3 patient neurons exhibit abnormal neurite outgrowth. (a) Phase-contrast image of control neuron and tracing (red: neurite,
blue: cell body outline, yellow: secondary branches) neuron at zero hour, fourth hour, eighth hour and twelfth hour. (b) Phase-contrast image
of SHANK3 neuron and tracing given below at zero hour, fourth hour, eighth hour and twelfth hour (scale= 50 μm), the arrows represent the
neurites formed every hour. (c) Primary neurite of formation/elimination rate were normalized to zero hour;41 represents the formation, o1
represents elimination. Data are presented as mean± s.e.m. (Two-way analysis of variance (ANOVA) performed, ***Po0.001 b/w genotypes,
***Po0.001 b/w genotypes and days). (d) Neurite extension/retraction rate of primary neurite were normalized to zero hour; 41 represents
the extension, o1 represents retraction. Data are presented as mean± s.e.m. (***Po0.001, two-way ANOVA performed). (e) Extension rate
(μm h− 1). (f) Retraction rate (μm h− 1). (g) Formation rate (neurite h− 1). (h) Elimination rate (neurite h− 1). Data are represented as mean± s.d.,
***Po0.001, **Po0.001, ***Po0.001, ***Po0.001 for panels (e–h), respectively. Unpaired Student’s t-test with Welch’s correction was
performed. (i) Cell soma speed (μm h− 1). (j) Change in cell soma area μm2 h− 1. Data are represented as mean± s.d. ***Po0.001 and
**P= 0.005 for panels (i) and (j), respectively, unpaired Student’s t-test with Welch’s correction was performed. Control neurons n= 51; SHANK3
neurons n= 59, from all three biological replicates. We compared four control lines with four SHANK3 lines, two control lines with one clonal
replicate of each and two SHANK3 lines with one clonal replicate of each.
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and number of primary neurites per neuron using high-content
imaging.
In the SHANK3 patient female line, (SHANK3 P2 C1) cell soma
area increased signiﬁcantly from 153.2 ± 6.5 to 238.6 ± 3.7 μm2
with SHANK3 overexpression (Figure 4d). Similarly, the SHANK3
male patient line (SHANK3 P1 C2) increased from 180.4 ± 3.2
to 250.4 ± 4.1 μm2 (Figure 4e). Hence, SHANK3 overexpression
rescued the cell soma phenotype. Cells infected with
control Myc-only virus showed no change (Supplementary
Figure 3C).
SHANK3 overexpression in SHANK3 P2 C1 also produced a
signiﬁcant decrease in the primary number of neurites (from
2.27 ± 0.09 to 1.24 ± 0.04 neurites: Figure 5b). However,
overexpression in SHANK3 P1 C2 did not bring about signiﬁcant
change in neurite number (Figure 5c). As both ﬁndings
were robust, we are currently unable to draw a ﬁrm con-
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clusion regarding the role of SHANK3 in this aspect of the
phenotype.
Morphogenetic deﬁcits reported in SHANK3 homozygous
knockout human ES cells
The SHANK3 rescue indicates that the morphogenetic phenotype
is a consequence of the reduced SHANK3 expression in the patient
cells. To conﬁrm this observation, we compared a human ES line
engineered to carry either one or two copies of a SHANK3
mutation discovered in ASD patients (es SHANK3+/− or es
SHANK3− /− ). These lines were compared with the parent ES line
(es SHANK3+/+). Cells were differentiated into placodal neurons
and then analyzed using high-content imaging at three stages of
neuralization; day 25, 27 and 30 (Figure 4i(i–iii)). At all the three
time points, both es shank3 +/− and es shank3− /− -derived
neurons had signiﬁcantly smaller cell soma than the es shank3 +/+
(Figure 4j, Supplementary Figure 5B(i–iii)). Similarly, both the es
shank3 +/− and es shank3− /−neurons had more neurites than
the es shank3 +/+ at all three stages (days 25, 27 and 30; Figure 4k,
Supplementary Figure 5a(i–iii)). Thus the es cells phenocopied the
deﬁcit observed in the SHANK3 patient lines, albeit at an earlier
stage, day 25 rather than day 30. This corresponds to our empirical
observation that these cells neuralize somewhat faster than
the iPSCs.
SHANK3 patient neurons show reduced actin
There are several molecular mechanisms that could be responsible
for the observed morphogenetic deﬁcits in SHANK3 patient lines.
We know from previous studies that SHANK3 has various actin-
binding partners, which regulate the neuronal cytoskeleton.
Therefore, we tested whether there were any changes in actin.
In Figures 5a–c, we see a reduction in both G and F actin intensity
in SHANK3 patient neurons at day 30 neuralization.
Several plausible mechanisms could link this actin phenotype to
the morphogenetic ﬁndings described above. Densin-180 is
known to bind to the N terminal ANK domain of SHANK3 protein
and thereby antagonize dendritic branching. SHANK3 binds to the
C terminus of densin-180, making the PDZ domain of densin-180
inaccessible to δcatenin. δcantenin binds with densin-180 and is
required for the formation of new branches.37 One hypothesis,
therefore, is that SHANK3 deﬁciency leads to more densin-180
being accessible to bind to δcatenin, which leads to an increase in
neurite formation. However, western blotting analysis of at day 30
of neuralization showed no changes in densin-180. Similarly,
another actin regulator cortactin, which also binds to SHANK3,
showed no changes in protein levels (Supplementary Figures 11C
and D). Altered expression of these proteins seems, therefore, not
to be part of the mechanism.
Another possibility emerges from a recent study, which showed
that SHANK3-deﬁcient mice exhibit a decrease in the levels of βPIX
and this, in turn, leads to a decrease in Rac1/PAK/LIMK activity. A
key downstream target of LIMK is coﬁlin, an actin-depolymerizing
factor that is inactivated when phosphorylated by LIMK.38–40 So,
when levels of LIMK decrease, more coﬁlin remains in the active
state resulting in increased depolymerization of actin. Coﬁlin
severs the actin ﬁlaments, which generates more actin ﬁlaments
or primers. These uncapped ﬁlaments are elongated by the Arp2/3
complex. This process helps form neurites.41,42
To test the hypothesis that coﬁlin is involved in the increased
neurite outgrowth observed in the SHANK3 cells, we examined
the ratio of phospho-coﬁlin to coﬁlin in day 30 neurons in both
patient and control lines. The patient cells showed a reduced
phospho-coﬁlin to total coﬁlin ratio (Figures 5d and e). To impute
function, we used a coﬁlin-blocking peptide (15 pmol g− 1—see
Duffney et al.40) at day 30 of neuralization to attempt to rescue the
neurite phenotype in the patient cells. Twenty-four hours of
treatment with the blocking peptide produces a decrease in the
number of neurite as shown in Figures 5f–h. This suggests
therefore that the reduced SHANK3 results in a decrease in Rac1/
RAK/LIMK activity leading to reduced phospho-coﬁlin and
ultimately increased neurite outgrowth.
DISCUSSION
In this study, we used neural cells from iPSCs derived from ASD
patients carrying SHANK3 microdeletions, plus human ES lines
engineered to carry SHANK3 mutations, to show both synaptic
and morphogenetic anomalies in comparison with control cells.
We used a SHANK3 rescue to conﬁrm that both phenotypes are
indeed the consequence of the SHANK3 haploinsufﬁciency.
Previously, studies in both rodents and human iPSC indicate that
deletion of SHANK3 disrupts synaptic signaling.19,21–25,43,44 The
reductions we see in synaptic puncta associated with SHANK3 are
consistent with those ﬁndings. Phenotypes in earlier neurogenesis
have not been observed, however, even though SHANK3 expression
Figure 4. Overexpression of SHANK3 rescues morphogenetic deﬁcits in immature SHANK3 patient neurons: (a) Day 30 SHANK3 neuron after
rescue (i), DCX (doublecortin; red) (iv), MYC (green) stained (ii), DAPI (4,6-diamidino-2-phenylindole; blue) (iii), (scale= 25 μm). (b) Number of
primary neurites per neuron SHANK3 Patient 2 clone 1 with and without rescue. (c) Number of primary neurites per neuron SHANK3 Patient 1
clone 2 with and without rescue. Data are represented as mean± s.e.m. Data compared via unpaired Student’s t-test with Welch’s correction.
(**P= 0.0026 SHANK3 P2 C1 before vs SHANK3 P2 C1 rescue, **P= 0.0066 SHANK3 P2 C1 before vs SHANK3 P2 C1 rescue-18). (d) Cumulative
frequency distribution of cell soma area (μm2) of SHANK3 Patient 2 clone 1 with and without rescue. (e) Cumulative frequency distribution of
cell soma area (μm2) of SHANK3 Patient 1 clone 2 with and without rescue. Data compared via Kolmogorov–Smirnov test. (***Po0.001
SHANK3 P2 C1 before vs SHANK3 P2 C1 rescue, ***Po0.001 SHANK3 P2 C1 before vs SHANK3 P2 C1 rescue-18, ***Po0.001 SHANK3 P1 C2
before vs SHANK3 P1 C2 rescue and ***Po0.001 SHANK3 P1 C2 before vs SHANK3 P1 C2 rescue-18). SHANK3 P2 C1 before n= 331, SHANK3
P2 C1 with rescue n= 749, SHANK3 P2 C1 with rescue -18 n= 557, SHANK3 P1 C2 before n= 689, SHANK3 P1 C2 with rescue n= 662, SHANK3
P1 C2 with rescue-18 n= 839 from all three biological replicates. (f) Day 70 control neurons stained with Homer1 (postsynaptic marker) and
Synaptophysin (presynaptic marker). Day 70 SHANK3 neuron stained with Homer1 (postsynaptic marker) and Synaptophysin (presynaptic
marker) (scale= 10 μm), arrows represent the co-localization of pre and post synaptic markers. (g) The average number of Synpatophysin
puncta per 50 μm. (h) The average number of Homer1 puncta per 50 μm. Signiﬁcant differences in expression of both Synaptophysin and
Homer1 were found. ***Po0.001 (unpaired Student’s t-test with Welch’s correction). Data are expressed as mean± s.e.m. We compared two
control lines with two SHANK3 lines (control neurons n= 46; SHANK3 neurons n= 41, from three biological replicates). (i) (i–iii) day 30 es shank3
+/+, es shank3 +/− and es shank3− /− -derived neurons stained with DAPI, DCX and Tuj1 (scale bar= 10 μm). (j) Cell soma area changes
through various neuralization stages (days 25–30). Data are represented as mean± s.e.m. Freidman’s two-way analysis of variance (ANOVA) by
ranks pairwise comparison ***Po0.001 on all three stages of neuralization. (k) The change in the number of primary neurites (days 25–30).
Data are presented as mean± s.e.m., (es shank3 shank3+/+ n= 5.1 × 103, es shank3+/− n= 5.0 × 103, es shank3− /− n= 5.11 × 103 from all
three biological replicates). Two-way ANOVA with repeated measure performed at each time point, ***Po0.001: signiﬁcant difference was
found between genotypes and **Po0.005: there is an interaction between days and genotypes. Bonferroni’s multiple comparisons test
revealed ***Po0.001 es shank3 +/+ vs es shank3+/− , ***Po0.001 es shank3+/+ vs es shank3− /− and P= 1.0 es shank3+/− and es
shank3− /− .
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is known to commence at neural tube stages, at least in Xenopus.26
Our study reveals that as SHANK3 patient olfactory placodal neurons
ﬁrst emerge, they develop smaller cell bodies and more and longer
primary neurites than the control neurons. Moreover, the SHANK3
neurons have deﬁcits in neurite extension and retraction and
reduced motility. Nonetheless, this phenotype is not found in the
cortical cells, a result consistent with the recent observations of Yi
et al.20 These results not only suggest that SHANK3 has a role in the
regulation of neuronal structure during early morphogenesis but
also suggests that this is an area-speciﬁc phenomenon as different
outcomes are observed in cortical and placodal neurons. We believe
our study provides the ﬁrst evidence for a SHANK3 phenotype, asso-
ciated with ASD, emerging soon after neurons become postmitotic
and considerably before the onset of synaptogenesis.
Figure 5. SHANK3 patient neurons show reduced F and G actin. (a) Phalloidin (green, F actin) and DnaseI (red, G actin) staining of control and
SHANK3 patient neurons (Scale= 20 μm). (b and c) Normalized (G and F) actin intensity. Data are presented as mean± s.e.m., *P= 0.029 and
*P= 0.0275 for panels (b) and (c), respectively, unpaired Student’s t-test with Welch’s correction was performed. (d and e) Western blotting of
Phospho-Coﬁlin/total Coﬁlin. Data are presented as mean± s.e.m., **P= 0.0025, unpaired Student’s t-test with Welch’s correction was
performed. (f and g). SHANK3 neurons at day 30/31 before and after addition of coﬁlin blocking peptide (scale= 50 μm). Data are presented as
mean± s.e.m., **P= 0.0032, unpaired Student’s t-test with Welch’s correction was performed.
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Smaller cell soma size has been consistently reported in both
postmortem and rodent models of ASD.45 Both Rett’s and Fragile
X syndrome show a reduction in cell soma size,46–53 and the
phenotype is also observed iPSC models of these diseases.54–56
The neurite phenotype is also likely to be of importance in ASD.
Peça et al.,24 studying the Shank3 knockout mice, traced Golgi-
stained striatal medium spiny neurons and found an increase in
total dendritic length. Similarly, Sholl analysis revealed neuronal
hypertrophy as measured by increased dendritic arborization.
These authors linked this to signiﬁcant enlargement of caudate
in Shank3 knockout mice. An enlarged caudate in autistic
patients is associated with repetitive behavior.57,58 Thus it is
possible that increased brain volume seen in autistic patients
could reﬂect the morphological changes we report here. None-
theless, the area speciﬁcity of these phenotypes clearly needs
further elucidation in cellular and animal models as well as in
postmortem material.
A limitation of this study is that we have analyzed only two iPSC
lines from each of the two SHANK3 patients. To consolidate these
ﬁndings, therefore, we employed genome-edited es lines to show
a similar phenotype to that seen in the SHANK3 iPSC patient lines.
Furthermore, we rescued the morphogenetic deﬁcits in the
patient cells by SHANK3 overexpression, conﬁrming the role of
SHANK3 in the genesis of the phenotype. We also conﬁrmed that
overexpression of SHANK3 subsequently increased both presy-
naptic synaptic and postsynaptic puncta signiﬁcantly in older
SHANK3 patient neurons (Supplementary Figure 10).
In conclusion, this study presents the novel idea that SHANK3
haploinsufﬁciency causes early structural deﬁcits in neurons,
which impact synaptic development. Moreover, we show a
phenotype arising in olfactory placodal neurons, destined for
the hypothalamus, consistent with suggestions of a functional
association between ASD and this brain structure. This study has
not only deﬁned a critical period during development when
cellular deﬁcits occur in ASD but has also determined a period for
successful rescue of these deﬁcits.
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